Biochemical characterization of cisplatin-resistance in MKN-45 human stomach adenocarcinoma cell line

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 3031-3036

  Hong, Weon Seon ^a   Son, Young Sook ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Cisplatin resistance; Fibronectin; MKN 45 cell; Superoxide dismutase

Indexed keywords

CARBOPLATIN; CATALASE; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FIBRONECTIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; SUPEROXIDE DISMUTASE;

ARTICLE; BIOCHEMISTRY; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL ADHESION; CISPLATIN; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; FIBRONECTINS; GLUTATHIONE; HUMANS; P-GLYCOPROTEIN; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0029958153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Waund WR: Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukeimia cells. Cancer Res 47: 6549-6555, 1987.
2. Kuppen PJK, Schuitemaker H, van't Veer LJ, de Bruijn EA, van Oosterom AT, and Schrier PI: Cis-diamminedichloroplatinum (II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48: 3355-3359, 1988.
3. Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tomakoshi K, Mizuno K, Kawai M, Suganuma N, and Tomoda T: Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells. Anticancer Res 13: 891-896, 1993.
4. Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T, and Saijo N: The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn J Cancer Res 84: 83-92, 1993.
5. Lewis AD, Hayes JD, and Wolf CR: Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle. Carcinogenesis 9: 1283-1287, 1988.
6. Nakagawa K, Yokota J, Wada M, Sasaki Y, Fujiwara Y, Sakai M, Muramatsu M, Terasaki T, Tsunokawa Y, Terada M, and Saijo N: Levels of glutathione S transferase π mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J Cancer Res 79: 301-304, 1988.
7. Pickett CB: Glutathione S-transferases: gene structure, regulation, and biological function. Annu Rev Biochem 58: 743-764, 1989.
8. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, and Saijo N: Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51: 3237-3242, 1991.
9. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, and Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
10. Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M, and Sugimachi K: Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin.Cancer 74: 1230-1236, 1994.
11. Yellin SA, Davidson BJ, Pinto JT, Sacks PG, Qiao C, and Schantz SP: Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines. Cancer Lett 85: 223-232, 1994.
12. Eastman A and Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 27: 4730-4734, 1988.
13. Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, One Y, Sasaki Y, Irino S, and Saijo N: Decreased accumulation as a mechanism of resistance to cis-diammine dichloroplatinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res 50: 2549-2553, 1990.
14. Masuda H, Tanaka T, and Takahama U: Cisplatin generates Superoxide anion by interaction with DNA in a cell free system. Biochem Biophys Res Commun 203: 1175- 1180, 1994.
15. Spitz DR, Phillips JW, Adams DT, Sherman CM, Deen DF, and Li GC: Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide resistant fibroblasts. J Cell Physiol 156: 72-79, 1993.
16. Calabresi P and Chabner BA: Chemotherapy of neoplastic diseases. In The pharmacological basis of therapeutics (Gilman AG, Rail TW, Nies AS, and Taylor P. eds) 8th ed. New York, Pergamon Press, 1991. pp 1202-1263.
17. Reed E, Yuspa SH, Zwelling LA, Ozols RF. and Poirier MC: Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Inv 77: 545-550, 1986.
18. Richon VM, Schulte N, and Eastman A: Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res 47: 2056-2061, 1987.
19. Chao CC, Huang YT, Ma CM, Chou WY. and Lin CS: Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharmacol 41: 69-75, 1992.
20. Roninson IB, Chin JE, Choi K, Gros P, Housman DE, Fojo A, Shem DW, Gottesman MM, and Pastan I: Isolation of human mdr DNA sequence amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83: 4538-4542, 1986.
21. Slovak ML, Ho JP, Bhardwa G, Kurz EU, Deeley RG, and Cole SPC: Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69 AR human tumor cell lines. Cancer Res 53: 3221-3225, 1993.
22. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC, and Sehested M: Sequential coexpression of the multidrug resistance genes MRP and mdr-1 and their products in VP-16 (etoposide) selected H69 small cell lung cancer cells. Cancer Res 55: 459-462, 1995.
23. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-428, 1993.
24. Mosman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55-63, 1983
25. Hong WS, Saijo N, Yasutsuna S, Minato K, Nakano H, Nakagawa K, Fujiwara Y, Nomura K, and Tweentyman PR: Establishment and characterization of cisplatin resistant sublines of human lung cancer cell lines. Int J Cancer 41: 462-467, 1988.
26. Choi YS and Gumbiner BM: Expression of cell adhesion molecule E-cadherin in Xenopus embryos begins at gastrulation and predominates in the ectoderm. J Cell Biol 108: 2449-2458, 1989.
27. Park SC, Kwak SJ, Kim EG, Rha YH, Song KY, and Kim ST: Immunohistochemical localization and biosignificance of glutathione transferase isoenzymes in human hepatoma tissues. Korean J Biochem 22: 147- 155, 1990.
28. Misra HP: Adrenochrome assay. In: CRC handbook of methods for oxygen radical research (Greenwald RA ed). Boca Raton, CRC Press Inc, 1985, pp 237-242.
29. Tritton TR: Cell death in cancer chemotherapy: the case of adriamycin In: Apoptosis, the molecular basis of cell death (Tomei LD and Cope FO eds), New York, Cold spring harbor laboratory press, 1991, pp 121-138.
30. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
31. Deffie AM, Batra JK, and Goldenberg GJ: Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res 49: 58-62, 1989.
32. Jong S, Zijlstra JG, de Vries EGE, and Mulder NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304-309, 1990.
33. Nitiss JL, Liu Y-X, and Hsiung Y: A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53: 89-93, 1993.
34. Jensen PB, Christensen IJ, Sehested M, Hansen HH, and Vindelov L: Differential cytotoxity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell line. Br J Cancer. 67: 311-320, 1993.